Tapewire

Nasdaq · USD

TNDM

TANDEM DIABETES CARE INC

Export transactions ↓
Tapewire entity
4682
SEC CIK
0001438133
Parsed reports
672

Last 12 months

Inside the activity.

0 purchase rows · 2 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202602
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
May 15, 2026 Filed May 19, 2026 20:15 UTC
Carpenter RickEVP & Chief Technology Officer
Tax withholdingCommon Stock 3,277 $12.82 $42,011.14
Disclosure

SEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 6

Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,582

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:15 UTC
Carpenter RickEVP & Chief Technology Officer
Exercise / conversionCommon Stock 6,439 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 5

Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,859

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:15 UTC
Carpenter RickEVP & Chief Technology Officer
Tax withholdingCommon Stock 457 $12.82 $5,858.74
Disclosure

SEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 4

Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,420

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:15 UTC
Carpenter RickEVP & Chief Technology Officer
Exercise / conversionCommon Stock 898 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 3

Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,877

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:15 UTC
Carpenter RickEVP & Chief Technology Officer
Tax withholdingCommon Stock 732 $12.82 $9,384.24
Disclosure

SEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 2

Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,979

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:15 UTC
Carpenter RickEVP & Chief Technology Officer
Exercise / conversionCommon Stock 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000068 · wk-form4_1779221737.xml · nonDerivative · entry 1

Carpenter Rick · CIK 0001513889 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,711

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionRestricted Stock Unit · Derivative 7,667 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · derivative · entry 11

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,335

Underlying: Common Stock · 7,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · derivative · entry 10

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,387

Underlying: Common Stock · 1,097 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · derivative · entry 9

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,437 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
GrantCommon Stock 1,886 $10.90 $20,557.40
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 7

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,171

F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Tax withholdingCommon Stock 3,901 $12.82 $50,010.82
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 6

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,285

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionCommon Stock 7,667 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 5

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Tax withholdingCommon Stock 559 $12.82 $7,166.38
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 4

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,519

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionCommon Stock 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 3

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Tax withholdingCommon Stock 732 $12.82 $9,384.24
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 2

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,981

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:12 UTC
Hansen Shannon MarieEVP & Chief Legal Officer
Exercise / conversionCommon Stock 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000064 · wk-form4_1779221525.xml · nonDerivative · entry 1

Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,713

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:10 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Exercise / conversionRestricted Stock Unit · Derivative 4,038 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · derivative · entry 4

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,077

Underlying: Common Stock · 4,038 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:10 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
GrantCommon Stock 434 $10.90 $4,730.60
Disclosure

SEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 3

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,105

F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
May 15, 2026 Filed May 19, 2026 20:10 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Tax withholdingCommon Stock 2,139 $12.82 $27,421.98
Disclosure

SEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 2

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,671

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:10 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Exercise / conversionCommon Stock 4,038 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 1

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,810

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 6,923 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · derivative · entry 10

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,845

Underlying: Common Stock · 6,923 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · derivative · entry 9

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,387

Underlying: Common Stock · 1,097 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · derivative · entry 8

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
GrantCommon Stock 1,336 $10.90 $14,562.40
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 7

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,770

F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 1,980 $12.82 $25,383.60
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 6

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,434

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 6,923 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 5

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 314 $12.82 $4,025.48
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 4

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,491

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 1,097 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 3

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 430 $12.82 $5,512.60
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 2

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,708

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:08 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000060 · wk-form4_1779221291.xml · nonDerivative · entry 1

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,138

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:02 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 10,496 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · derivative · entry 6

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,992

Underlying: Common Stock · 10,496 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan.

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:02 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 76 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · derivative · entry 5

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304

Underlying: Common Stock · 76 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:02 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Tax withholdingCommon Stock 7,854 $12.82 $100,688.28
Disclosure

SEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · nonDerivative · entry 4

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,317

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:02 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionCommon Stock 10,496 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · nonDerivative · entry 3

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:02 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Tax withholdingCommon Stock 57 $12.82 $730.74
Disclosure

SEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · nonDerivative · entry 2

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,675

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:02 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionCommon Stock 76 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000054 · wk-form4_1779220921.xml · nonDerivative · entry 1

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 39,735 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 10

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,471

Underlying: Common Stock · 39,735 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Awarded on May 30, 2025 pursuant to the 2023 Plan.

F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 5,982 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 9

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,929

Underlying: Common Stock · 5,982 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended.

F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 5,472 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · derivative · entry 8

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,472 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
GrantCommon Stock 1,336 $10.90 $14,562.40
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 7

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,443

F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 18,944 $12.82 $242,862.08
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 6

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,107

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 39,735 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 5

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,051

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 3,044 $12.82 $39,024.08
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 4

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,316

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 5,982 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 3

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,360

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 2,785 $12.82 $35,703.70
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 2

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,378

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2026 Filed May 19, 2026 20:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 5,472 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000058 · wk-form4_1779221206.xml · nonDerivative · entry 1

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,163

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:10 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Exercise / conversionRestricted Stock Unit · Derivative 3,636 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · derivative · entry 3

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,181

Underlying: Common Stock · 3,636 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:10 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Tax withholdingCommon Stock 1,926 $20.66 $39,791.16
Disclosure

SEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · nonDerivative · entry 2

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,772

F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
April 15, 2026 Filed Apr 17, 2026 20:10 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
Exercise / conversionCommon Stock 3,636 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · nonDerivative · entry 1

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,698

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 20:06 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
SaleCommon Stock 187 $23.05 $4,310.35
Disclosure

SEC source: 0001438133-26-000023 · wk-form4_1773864360.xml · nonDerivative · entry 3

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,656

F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.